HYL Hyloris Pharmaceuticals SA
Hyloris Pharmaceuticals SA operates as a specialty pharmaceutical company in Belgium, the United States, Europe, the Middle East, Africa, and Asia-Pacific. The company offers Maxigesic IV for the treatment of post-operative pain; Podofilox gel, a topical antimycotic drug for external genital and perianal warts; Sotalol IV, an intravenous formulation of sotalol for the treatment of atrial fibrillation, and life-threatening ventricular arrhythmias; and Valacyclovir oral suspension for the treatment of herpes virus infections. It also provides Atomoxetine oral liquid for the treatment of attention deficit hyperactivity disorder; XTRAZA and Tranexamic Acid IV RTU for the prevention and treatment of excessive bleeding; HY-094 Iron IV to treat iron deficiency; and Pantoprazole IV for short-term treatment of adult patients with gastroesophageal reflux disease and a history of erosive esophagitis. In addition, the company is involved in the development of Alenura for painful bladder syndrome; Phosphate oral liquid for phosphate supplementation; and HY-095 PPI for the treatment of gastric ulcers in horses. Further, it develops Aspirin IV for acute coronary syndrome indication; Milrinone for late-stage HF with LVAD; Dofetilide IV for atrial fibrillation indication; HY-074 for acute coronary syndrome indication; Metolazone IV for congestive heart failure indication; and HY-75 for coronary heart disease indication. The company has collaboration agreements with FHP BV, Pleco Therapeutics, Vaneltix Pharma, Inc., and AFT Pharmaceuticals. Hyloris Pharmaceuticals SA was incorporated in 2012 and is headquartered in Liège, Belgium.…
Industry Peers
BiotechnologyKey Statistics
About Hyloris Pharmaceuticals (EBR: HYL)
›
Hyloris Pharmaceuticals (EBR: HYL) is listed on Euronext Brussels, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 54 employees.
The shares were at 4.150 EUR on 20 November 2026, down 29.7% over 52 weeks. Its 52-week range is 3.320 EUR to 8.400 EUR: the price is 50.6% below the high and 25.0% above the low.
Its market capitalisation is 116.20M EUR.
Hyloris Pharmaceuticals reports return on equity of -23.9%, an operating margin of -61.4% and revenue up 56.5% year over year.
It holds more cash than debt, a net cash position of 7.27M EUR. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 3 analysts cover the stock, with an average rating of Buy; their mean price target of 11.23 EUR is 170.7% above the current price. The next earnings report is expected on 25 March 2027.